Haemonetics Corporation EBITDA Margin for the Trailing 12 Months (TTM) ending March 29, 2025: 20.57%

Haemonetics Corporation EBITDA Margin is 20.57% for the Trailing 12 Months (TTM) ending March 29, 2025, a 3.47% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.
  • Haemonetics Corporation EBITDA Margin for the Trailing 12 Months (TTM) ending March 30, 2024 was 19.89%, a -6.80% change year over year.
  • Haemonetics Corporation EBITDA Margin for the Trailing 12 Months (TTM) ending April 01, 2023 was 21.34%, a 18.77% change year over year.
  • Haemonetics Corporation EBITDA Margin for the Trailing 12 Months (TTM) ending April 02, 2022 was 17.96%, a -10.15% change year over year.
  • Haemonetics Corporation EBITDA Margin for the Trailing 12 Months (TTM) ending April 03, 2021 was 19.99%, a -7.49% change year over year.
Key Data
Date EBITDA Margin Net Income Margin EBT Margin Operating Income Margin